Summary of 4-month treatment trials in pulmonary tuberculosis, indicating their design, unfavourable rate and follow-up
| Study [ref.] | Experimental regimen duration | Regimens | Patients on experimental arms n | Relapse or unfavourable rate % | Follow-up |
| Second French study [79] | 18 weeks | 2SHRZ/HRZ | 180# | 3 | 24 months |
| Mehrotra et al. [80] | 19 weeks | 3SHRZ/RH | 0 | 12 months | |
| 3SHRZ/SHZ | 0 | ||||
| 3SHRZEmide | 5 | ||||
| East African/British Medical Research Council [81] | 19 weeks | 2SHRZ/2HRZ | 104 | 16 | 24 months |
| 2SHRZ/2RH | 104 | 11 | |||
| 2SHRZ/2HZ | 98 | 32 | |||
| 2SHRZ/2H | 105 | 30 | |||
| 2HRZ/2H | 100 | 40 | |||
| Singapore/British Medical Research Council [82] | 4 months | 2SHRZ/HRZ | 80 | 11 | >24 months |
| 2SHRZ/HR | 81 | 6 | |||
| REMoxTB [9] | 17 weeks | 2MHRZ/2MHR | 655 | 15 | 12 months |
| 2EMRZ/2MR | 636 | 20 | |||
| RIFAQUIN [10] | 4 months | 2MHRZ/2MRp (twice weekly) | 275 | 18.2 | 12–18 months |
| OFLOTUB [11] | 4 months | 2HRZG/2HR | 694 | 21 | 24 months |
S: streptomycin; H: isoniazid; R: rifampicin; Z: pyrazinamide; Emide: ethionamide; M: moxifloxacin; E: ethambutol; Rp: rifapentine; G: gatifloxacin #: 204 patients in the trial and data analysed from 180.